MS patients have elevated titers of EBV-specific antibodies in serum and show signs of CNS damage only after EBV infection. Dr Tilman Schneider-Hohendorf (University of Münster, Germany) explained that a preceding study by his group showed that MS is associated with a broader MHC-I-restricted EBV-specific T-cell receptor beta chain (TRB) repertoire than controls [1]. “This can be interpreted as an imprint of an aberrant primary or ongoing ineffective response to EBV in MS.” The researchers wanted to know if the ineffective response to EBV in MS extends to NMOSD, MOGAD, and Susac syndrome [2]. They also evaluated whether this ineffective EBV response can be influenced by MS therapies.
Dr Schneider-Hohendorf and colleagues sequenced blood samples of cohorts with NMOSD, MOGAD, and Susac syndrome who were matched with patients with MS and healthy controls, balanced for age, sex, and HLA alleles. They found that, other than in MS, none of the evaluated diseases presented with a broader anti-EBV TRB repertoire.
Furthermore, modulation of the broader anti-EBV TCR repertoire by ocrelizumab, teriflunomide, and dimethyl fumarate was observed, but not by interferon-beta or glatiramer acetate. None of the DMTs modulated an anti-cytomegalovirus response. Dr Schneider-Hohendorf offered 2 possible explanations for these findings: “Either there is a direct depletion of anti-EBV-specific CD8+ cells; or a more indirect mechanism whereby EBV-infected B cells are depleted in large numbers, and subsequently less of an EBV response is required.”
Future studies will have to demonstrate whether the observed modulation of the EBV response by some of the DMTs directly contributes to their clinical efficacy.
- Schneider-Hohendorf T, et al. J Exp Med. 2022 Nov 7;219(11):e20220650.
- Schneider-Hohendorf T, et al. Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation. Abstract O133, ECTRIMS 2024, 18–20 September 2024, Copenhagen, Denmark.
Medical writing support was provided by Michiel Tent
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Liraglutide achieves 5.8% reduction in BMI for children aged 6-12 Next Article
Transfer of ocrelizumab into breastmilk is negligible »
« Liraglutide achieves 5.8% reduction in BMI for children aged 6-12 Next Article
Transfer of ocrelizumab into breastmilk is negligible »
Table of Contents: ECTRIMS 2024
Featured articles
Revised McDonald criteria allow earlier and more precise MS diagnosis
Tolebrutinib slows disability in non-relapsing secondary progressive MS
Online First
Revised McDonald criteria allow earlier and more precise MS diagnosis
Blood markers predict MS progression
High depression genetic burden associated with MS disease activity
More comorbidity is associated with worse clinical outcomes in MS
First-line moderate-efficacy DMTs show similar efficacy
Tolebrutinib slows disability in non-relapsing secondary progressive MS
Frexalimab shows favourable safety and efficacy in OLE
Transfer of ocrelizumab into breastmilk is negligible
Ineffective response to EBV in MS not seen in similar diseases
Encouraging real-world results of AHSCT to treat aggressive MS
Tolebrutinib slows disability worsening in relapsing MS
High-dose simvastatin does not slow disability progression in SPMS
Gut microbiota modulates inflammation and cortical damage
Related Articles
September 10, 2020
Alemtuzumab efficacy and safety data of over 9 years
December 20, 2022
Autologous haematopoietic stem cell transplantation versus DMTs
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com